

Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations

Pascal Juillerat^{a, b} Michael Manz^c Bernhard Sauter^d Jonas Zeitz^{d, e}
Stephan R. Vavricka^{e, f} on behalf of the Swiss IBDnet, an official working group
of the Swiss Society of Gastroenterology

^aUniversity of Bern, Maurice E Müller Laboratories, Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Bern, Switzerland; ^bDepartment of Gastroenterology, Clinic for Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland; ^cDepartment of Gastroenterology and Hepatology, Clarunis, Basel, Switzerland; ^dCenter of Gastroenterology, Clinic Hirslanden, Zürich, Switzerland; ^eDivision of Gastroenterology and Hepatology, University Hospital, Zürich, Switzerland; ^fGastroenterology and Hepatology Center, Zürich, Switzerland

Keywords

Extraintestinal manifestations · Crohn's disease · Ulcerative colitis · Inflammatory bowel disease · Infliximab · Ankylosing spondyloarthritis

Abstract

Extraintestinal manifestations (EIM) have become an important source of morbidity and disability as well as an identified risk factor for an unfavorably course of disease in inflammatory bowel diseases (IBD). Therefore, efforts have been put into a more global and interdisciplinary management of IBD patients in collaboration with rheumatologists, dermatologists, and ophthalmologists. A real therapeutic success has also been obtained with a more “systemic” IBD treatment associated with the development of monoclonal antibodies against TNF alpha and biological agents derived from the treatment of rheumatological disease (also called biological Disease-Modifying Antirheumatic Drugs). The prevalence of these EIM remains too low to undergo randomized controlled trials with this specific focus and therefore the evidence relies on case series and experts' opinions, which low-

ers the level of evidence. After a careful review of the most recent literature, this paper aims to update the reader on the latest therapeutic management of IBD patients with EIM.

© 2020 S. Karger AG, Basel

Introduction

Extraintestinal manifestations (EIM) occur in about 50% of inflammatory bowel disease (IBD) patients over the course of their disease. The prevalence has initially been rather underestimated [1], but more recent cohorts reported on the increasing importance of this phenomenon [2].

The pathogenesis of the inflammation in IBD seems directly associated to it, as it acts beyond the gastrointestinal tract, making it a systemic disease. The most frequent EIM are distributed in 4 groups: musculoskeletal, ophthalmic, dermatological, and hepatobiliary disorders and could occur with or without a link to disease activity.

The development of EIM has a major impact on patient quality of life, increases the morbidity of these dis-

Table 1. Characteristics of the most frequent EIMs

EIM	Parallel course of IBD	Separate course of IBD	May or may not parallel disease activity	Response to anti-TNF agents
Axial arthropathy		✓		+++
Peripheral arthropathy	✓ (Pauciarticular)	✓ (Polyarticular)		++
Erythema nodosum	✓			++
Pyoderma gangrenosum			✓	++
Oral aphthous ulcers	✓			++
Episcleritis	✓			++
Uveitis			✓	+++
Primary sclerosing cholangitis			✓	-

EIM, extraintestinal manifestation; IBD, inflammatory bowel diseases.

eases, and disability of IBD patients. This manifestation can occur before, at, or after the diagnosis of IBD and, if present, should, in the presence of highly suggestive EIM, motivate the search for an underlying IBD, thereby reducing the diagnostic delay. This has been nicely shown in the prospective Swiss IBD cohort study where about one-fourth of patients had EIM symptoms before IBD diagnosis was made [3].

Consequently, the caregivers have to take the patients with these manifestations more globally into consideration when deciding on a specific treatment and seek for the help of a multidisciplinary management including, among others: rheumatologists, dermatologists, and ophthalmologists. In the specific group of primary sclerosing cholangitis (PSC) patients, a life-threatening risk is present due to a much higher risk of development of neoplasia.

This review details the classification of the most common EIM, their characteristics, and treatment (Table 1). Extraintestinal complications of IBD, such as anemia, vitamin deficiency, or urolithiasis and associated diseases, are beyond the scope of this review.

Rheumatological and Musculoskeletal Manifestations

Articular manifestation affects approximately 30% of patients with patients with IBD, more Crohn's disease (CD) than ulcerative colitis (UC) [2, 4]. Peripheral joint pain is the most common EIM in patients with IBD; they are mostly noninflammatory and thus not comparable to inflammatory joint manifestations, which usually do not follow the course of disease and run independently [5].

IBD-associated axial arthritis is considered as a subgroup of the spondylarthropathies (SpA) by rheumatologists [6]. Interestingly, on the other hand, approximately 75% of patients with rheumatological disease will eventually develop digestive symptoms and even gut inflammation, but only about 7% will end up with an diagnosis of IBD [7] which is then considered as “extra-articular manifestation” [8]. However, it is also possible that the real prevalence of coexistence of IBD and EIM is underestimated in some patients who develop initially an EIM and are treated with biologicals that could mask the digestive involvement. The pathophysiological concept of the gut-joint axis is advocated to underlie these manifestations. Indeed, genetic studies highly suggest a link with genes, which may be implied in both disease phenomenon [9–12] and, that is, some receptors influencing bacterial impact on the gut and joints inflammation, such as scavenger receptor CD 163 on the macrophages surface, could also play a role [13, 14]. The idea of an aberrant homing of mucosal T cells and extraintestinal manifestations of IBD [15] has been also recently hypothesized in an interesting publication from Dubinsky et al. [16] to explain the link between an obvious higher rate of EIM and the use of vedolizumab in UC. The authors hypothesized that the natural homing of active lymphocytes, which migrate from the blood into the lymphoid tissues, regulated by adhesion molecules and chemokines, is voluntarily impaired (basic mechanism of the drug). By that mean, more activated lymphocytes remain in the circulation, traffic to other organ system and probably aberrantly bind to inflamed synovial vessels. This aberrant homing to the joints does not depend on a4b7-MAcAM-1 interactions; however, several other adhesion molecules result (e.g., VAP-1) could act [17].

Table 2. Classification of enteropathic peripheral arthropathy associated with IBD. Adapted by S. Vavricka from the original article from [195]

Definition	Type I (pauci-articular)	Type II (polyarticular)
Prevalence CD, UC	6%, 3.6%	4%, 2.5%
Involvement	Asymmetric, <5 joints	Can be symmetric or asymmetric, may be erosive, 5 or more joints
Location	Mainly large joints: knee > ankle > wrist > elbow > MCP > hip > shoulder	Mainly small joints: MCP > knees >> PIP > wrist > ankle > elbow > shoulder
Parallels disease activity	Yes, similar to a reactive arthritis (e.g., post dysenteric)	No clinical course independent of IBD activity could predated the diagnosis of IBD
Natural course	Self-limited episodes that last <10 weeks	Persistent inflammation for months or even years
Associated	With HLA-B27, B35, and HLA-DR 103 with high frequency of EN and uveitis.	With HLA-B44 with uveitis

IBD, inflammatory bowel diseases; CD, Crohn's disease; UC, ulcerative colitis; MCP, metacarpophalangeal joint; PIP, proximal interphalangeal joints; HLA, human leukocyte antigen; EN, erythema nodosum.

IBD-Associated Axial and Peripheral Arthropathies

Peripheral arthropathies are described in the IBD literature as 2 types (1 and 2) [18] of which distinct characteristics and behaviors presented in Table 2. IBD axial arthropathy is considered as a subgroup of SpA, which are a chronic inflammatory disease of the axial skeleton and/or peripheral joints and also include ankylosing spondylitis (AS), psoriatic arthritis, reactive arthritis, and undifferentiated SpA. Axial SpA occurs in 4–10% of CD patients, and making these diagnoses based on inflammatory back pain is a challenge for the gastroenterologist. A recent publication and review of >250 patients from the Netherland conclude to an interesting and relevant referral algorithm for suspected axial spondyloarthritis in IBD patients. First, perform an anterior-posterior X-ray to search for a sacroiliitis (could be MRI in young patients to minimize radiation and make earlier diagnosis), when positive refer the patient. However, when negative, check for other SpA features such as inflammatory back pain, enthesitis, dactylitis, uveitis, positive family history, IBD, alternating buttock pain, psoriasis, arthritis, good response to nonsteroidal anti-inflammatory drugs (NSAID), elevated ESR/CRP, and perform an HLA-B27 serology. If ≥ 4 SpA features or 2–3 with positive HLA B-27, then referred (high probability of having axial SpA). Finally, patients with a positive HLA-B27 test and the presence of ≤ 1 SpA feature should undergo MRI [19]. This practical procedure is very close to the Assessment of SpondyloArthritis International Society criteria use for the diagnosis, summarized in Table 3.

Treatment of Arthropathies with Conventional Disease-Modifying Antirheumatic Drugs and Anti-TNF Alpha Agents (Biological Disease-Modifying Antirheumatic Drugs)

Patients with IBD-associated SpA are commonly treated with physical therapy and NSAIDs to relieve pain, swelling, and stiffness. Frequently used with success by rheumatologists, NSAIDs represent a very controversial option for IBD patients [20, 21] as that they have been accused of inducing increased rate of flares, hospitalization, and complications [22, 23], which are not found in a recent meta-analysis [24]. Therefore, NSAIDs should be used in the short term [25], or COX-2 inhibitors are an alternative option, as less negative data exist [26, 27], or paracetamol in case of residual pain or only minimal inflammation. Glucocorticoid injections directed to the local site of musculoskeletal inflammation may also be considered. Patients with axial disease should not receive long-term treatment with systemic glucocorticoids, as stated in the European League Against Rheumatism recommendations [25, 28]. Alternative drugs for resistant peripheral arthritis only are the Disease-Modifying Antirheumatic Drugs (DMARD) sulfasalazine and methotrexate. The use of these old drugs is mostly based on the recommendation for the treatment of AS [28]. The anti-metabolite drug, methotrexate, is rather used in CD patients due to strongest evidence for the bowel disease and preferably for the indication of maintenance of a drug-induced remission or in combination with biologics [29].

Table 3. Inflammatory back pain criteria sets and mnemonic for assessment of axial spondyloarthritis, according to ASAS. Adapted from [196]

<i>In patients with back pain ≥3 months and age at onset back pain <45 years (with/without peripheral manifestations)</i>	
(1) Sacroiliitis on imaging	One or more SpA feature(s)
– Active (acute) inflammation on MRI highly suggestive of sacroiliitis associated with SpA	– Inflammatory back pain
– Definite radiographic sacroiliitis according to modified New York criteria	– Arthritis
	– Enthesitis
	– Uveitis
	– Dactylitis
	– Psoriasis
	– CD/UC
	– Good response to NSAIDS
	– Family history for SpA
OR	Two or more SpA feature(s)
(2) HLA-B27 positivity	– HLA-B27
	– Elevated CRP
SpA, spondyloarthritis; ASAS, Assessment of SpondylArthritis international Society; NSAIDS, nonsteroidal anti-inflammatory drugs; CRP, C-reactive protein; CD, Crohn’s disease; UC, ulcerative colitis.	

Finally, biological agents are, for now >20 years, the most efficient class of drugs to control all these rheumatologically manifestations, demonstrated in randomized clinical trials [30] as well as historical cases series [31, 32]. The indication of the most commonly used anti-TNF agents, infliximab [33] and adalimumab [34, 35], is multiple, and the efficacy reach a good level and also drives a high number of indications in IBD patients, as demonstrated recently in the Swiss IBD cohort study [36]. Paradoxical articular manifestations are also frequently described in IBD patients under anti-TNF treatment and do not warrant the need of discontinuation of the medication [37]. Golimumab [38, 39] and Certolizumab [40] are also other TNF inhibitors to consider when treating rheumatological EIM, in particular after a loss of response to infliximab due to autoimmunity (antibodies against the drug) [41, 42]. Finally, Vedolizumab, a gut-specific anti-integrin inhibitor, that blocks leucocytes migration to the inflammation site seems to influence mostly arthropathies linked to disease activity (Type II) in about 40% of the patients according to a small prospective French study [43], but also incidental inflammatory arthralgia/arthritis has been described in 14%, similarly to the publication from Mount Sinai Hospital [16]. The theoretical hypothesis of the authors of the latter study is that Vedolizumab administration may lead to the trafficking of $\alpha 4\beta 7$ -expressing lymphocytes to other organ systems and may predispose patients to develop EIMs with a parallel course to IBD.

Treatment of Arthropathies with Future IBD Therapies

Based on European League Against Rheumatism recommendations [28], biological DMARDs should be considered in patients with persistently high disease activity despite conventional treatment. Current practice is to start with TNF alpha therapy; however, most of IBD patients will eventually fail anti-TNF alpha agents due to either gastroenterological or rheumatological source of activity. That leads to the assumption that small molecules, acting as targeted DMARDs, such as tofacitinib or other more specific medication like JAK 1 inhibitors (upadacitinib, folgitinib, baricitinib, peficitinib) will be used probably early in the disease course of these IBD patients with EIM [44]. Of note, Apremilast (Otezla[®]), which phase III trial was not conducted in UC, as well as ustekinumab (Stelara[®]), which should soon have indication in IBD, did not demonstrate efficacy in rheumatoid arthritis. Data are also disappointing in SpA patients treated with ustekinumab. Therefore, small molecules such as apremilast and kinase inhibitors are clearly entering the field as potential new treatment options. A detailed overview is presented in Table 4 (with their references) and commented below.

Tofacitinib, a pan-JAK inhibitor in doses of 5 and 10 mg twice daily, has also been evaluated in phase II trials for clinical efficacy in patients with AS with promising results [45]; however, no further trials are planned for this

Table 4. Current stand of JAK inhibitors (and other small molecules), IL-6, IL-12, IL-17 inhibitors tested in rheumatological diseases and IBD

Name	Molecule	CD	UC	Rheumatoid arthritis	Ankylosing spondylitis	Psoriasis/PsA
Tofacitinib (1st gen.) CP690550	Pan-JAK inhibitor	☺ Pilot, phase IIb study [136, 137] ✓ Real life data ✓ OLE study [138] ✓ Objective inflammation [139]	Approved 2018 (Xeljanz [®]) [140, 141]	Approved 2012 [142] as efficient as adalimumab [142]	✓Phase IIb study [45] but than discontinued	Approved for PsA, but not psoriasis [143, 144]
Upadacitinib (2nd gen.) ABT-494	JAK1 selective inhibitor	✓ Phase IIb study [145] ✓ Effect on EIM [46] Ongoing phase III	✓ Phase IIb study [146, 147] Ongoing phase III	✓ Phase III [148]	No studies	No studies
Folgitinib (2nd gen.) GLPG0634	JAK1 selective inhibitor [149]	✓ Phase IIb study [150] Ongoing phase III	Ongoing phase III	✓ Phase III = FINCH 3 study	✓ Phase II	✓ Phase II
Baricitinib (1st gen.) INCB-28050/LY-3009104	JAK1/JAK2 selective inhibitor	No studies	No studies	Approved 2017 (Olumiant [®]) [151, 152]	No studies	✓ Phase IIb [153] only for PsA
Peficitinib (1st gen.) GLPG1205 ASP-015K, JNJ-54781532	JAK3 selective inhibitor	No studies	☺ Phase IIb [154]	✓ Phase III [155]	No studies	discontinued
Apremilast NCT02289417	Phosphodiesterase 4 – inhibitor	No studies	✓ II [156, 157]/ will not undergo phase III	☺ Phase II [158]	✓ Phase II [159] ✓ Subgroup of phase III [160]	Approved 2014 (Otezla [®]) [161–163]
Tocilizumab	Anti-IL-6 receptor	✓ Pilot study [164]	☺ 1 case report of exacerbation [165] 1 case of improvement [166]	✓ Approved 2010 (Actemra [®]) [167] Higher risk of intestinal perforation [168]	☺ Phase II–III [169]	No studies
Ustekinumab NCT02407236	Anti-IL 23/12 (p40 Inhibitor)	✓ Approved 2016 (Stelara [®]) [170]	✓ Phase III	☺ Phase II [171]	☺ Phase III	✓ Approved 2013 for PsA [172, 173] 2009 for Psoriasis [174, 175] (Stelara [®])
Briakinumab ABT-874 NTC00570986	Anti-IL 23/12 (p40 inhibitor)	✓ Phase IIb [176]	No studies	No studies	No studies	✓ Phase III [177] But withdrawal of FDA application due to severe adverse events.
Risankizumab ABBV 066, BI 6555066	Anti-IL 23 (p19 Inhibitor)	✓ Phase II [178] ongoing phase III	Ongoing phase III	No studies	☺ Phase II [50]	✓ Approved 2019 for Psoriasis (Skyrizi [®]) [179] ✓ Phase II for PsA [180]
Brazikumab MEDI2070/AMG-139	Anti-IL 23 (p19 Inhibitor)	✓ Phase IIa [181]	No studies	No studies	No studies	No studies
Guselkumab CNTO1959	Anti-IL 23 (p19 Inhibitor)	Ongoing phases II/III (galaxi)	Ongoing phases II/III	☺ Phase II [171]	✓ Phase II	✓ Approved 2017 for psoriasis (Tremfya [®]) [182, 183] ✓ Phase II for PsA [184]
Mirikizumab LY3074828	Anti-IL 23 (p19 inhibitor)	✓ Phase II [185]	✓ Phase II [186, 187]	No studies	No studies	✓ Phase II [188]
Brodalumab AMG 827/KHK4827	Anti-IL-17 RA	☺☺☺ Worsen, phase IIa [189]	No studies	No studies (phase II canceled)	✓ Phase III [190]	✓ Approved 2017 (Siliq [®] , Kyntheum [®]) [191]
Secukinumab AIN457, KB03303A	Anti-IL-17 A	☺☺☺ Worsen, phase IIa [49]	No studies	✓ Phase III [192]	✓ Approved 2016 (Cosentyx [®]) [193]	✓ Approved 2015 (Cosentyx [®]) [194]

IL, interleukin; IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; PsA, psoriatic Arthritis.

additional indication. Similarly, baricitinib and ruxolitinib, which have a very similar spectrum of cytokine blockade to that of tofacitinib, have not been tested in IBD patients but probably have clinical potential. One reason could be the emergence of a “second generation” of JAK inhibitors for the treatment of immune-mediated diseases that exert a selective blockade of JAK1 or JAK3 which, in theory, should have less risk of hematopoietic toxicity, an effect largely secondary to JAK2 inhibition. Promising data have been recently presented at the European Crohn’s and Colitis Organization congress in 220 upadacitinib-treated CD patients showing a resolution of >50% of the EIM with appropriate dosage of the drug compared to about 30% under placebo [46].

Biologics targeting interleukin (IL)-17 signaling have been approved for clinical use in AS. However, this mode of inhibition has demonstrated a deleterious effect with increased activity in CD patients in a phase III trial using secukinumab against placebo [47]. As a plausible explanation, a major alteration of intestinal barrier function associated with IL-17 inhibition and dysbiosis have been demonstrated in mouse models [48, 49]. Targeting specifically the IL-23/12 pathway seems also quite disappointing, as the anti-IL-23 biologic, risankizumab, failed to meet its primary endpoint in terms of efficacy in SpA [50] and ustekinumab, with a brighter spectrum, did not show enough efficacy in a phase III study in rheumatoid diseases [51]. Fingolimod and other, more selective, S1PR modulators are being developed for clinical use in IBD, but have, to our knowledge, not been tested in rheumatoid diseases.

Dermatological Manifestations

Up to 15% of IBD patients present with cutaneous EIM [2, 52]. These complications are usually diagnosed after excluding other skin disorders.

Erythema Nodosum

The frequency of erythema nodosum associated to IBD can reach up to 15% of CD and 10% of UC in some studies [52–54]. Erythema nodosum often coexists with eye and joint involvement, isolated colonic disease, and pyoderma gangrenosum. It presents with subcutaneous nodules, which are raised, tender, and red/violet and are typically located on the anterior part of the lower extremities. Rarely other body parts are involved [52]. Erythema nodosum is often self-limiting, and it depends on the activity of the underlying disease [55].

In mild cases, topical corticosteroids, use of analgesics, compression stockings, and leg elevations were used [56]. Severe disease courses are treated with systemic corticosteroids, immunosuppressive therapies, or TNF antibodies [57–61].

Pyoderma Gangrenosum

Pyoderma gangrenosum is a cutaneous EIM, which is more common in UC than in CD and affects women more frequently than men [61, 62]. Pyoderma gangrenosum often coexists with a familial history of UC, in patients with pancolitis, permanent stoma, eye involvement, and erythema nodosum, and it is more prevalent in African-Americans [54]. The prevalence of pyoderma gangrenosum in IBD is 0.4–2% [1, 2, 53, 63, 64]. Most pyoderma gangrenosum lesions occur after a trauma (even years later), a phenomenon, which is known as pathergy. The lesions start as a small pustule, which spreads rapidly and develops deep purulent ulcers [65]. They mostly occur on extensor surfaces of the legs (shins) and adjacent to a postsurgical stoma, but can occur anywhere on the body, including the genitalia [66]. Pyoderma gangrenosum may improve if the underlying IBD is treated successfully. Mild cases usually respond to local and topical therapy. Unusually, intralesional corticosteroid injections, moist treatment with hydroactive dressings, and topical sodium cromoglycate are used [65, 67]. In more severe cases, systemic therapies such as oral sulfasalazine, dapsone, corticosteroids, and immunomodulators (azathioprine, cyclophosphamide, cyclosporine, methotrexate, tacrolimus, and mycophenolate mofetil) are used [56, 65, 68, 69]. TNF-antibody therapy has shown good therapeutic results in several case series and case reports for infliximab [70–76] and for Adalimumab [77, 78]. A success rate comparable to therapy of luminal IBD (>60%) has been described in cases series of PG treated with infliximab [70–76], but mostly linked to publication bias. For an overview on TNF-antibody therapies in EIM, please see reference [79].

Sweet Syndrome

Sweet syndrome, or acute febrile neutrophilic dermatosis, is a rare dermatologic manifestation associated with CD and UC [80, 81]. Sweet syndrome is not only associated with IBD but also can occur in other systemic diseases and malignancies. Sweet’s syndrome manifests as tender or papulosquamous exanthema or nodules involving the arm, legs, trunk, hands, or face. Laboratory and histological features of Sweet’s syndrome are leukocytosis and a neutrophilic infiltrate. Patients present usually with

arthritis, fever, and ocular symptoms, mainly conjunctivitis. Its association with IBD usually parallels the gastrointestinal disease activity but may precede the diagnosis of IBD [82]. IBD patients with Sweet's syndrome respond to topical or systemic corticosteroid therapy [83] and heal without scarring. Metronidazole has been reported to be effective in one case report [82].

Oral Aphthous Lesions

Mainly in CD patients, the oral cavity of IBD patients can be affected. Besides periodontitis, aphthous lesions can occur. In severe cases, this is called pyostomatitis vegetans [2, 84–86]. Oral aphthous lesions usually follow the course of the underlying IBD. Aphthous lesions are typically located on the labial and buccal mucosa but may also affect the tongue and oropharynx. Pyostomatitis vegetans manifests as multiple pustular sometimes hemorrhagic eruptions anywhere on the oral mucosa with a cobblestone pattern. Antiseptic mouthwashes and topical steroids are used as therapy [56, 87].

Hepatological Manifestations

Steatosis and other Frequent Liver Diseases

The most frequent (1.5–55%) hepatic extraintestinal complications of IBD patients are the nonalcoholic fatty liver disease (from steatosis to nonalcoholic steatohepatitis, or even cirrhosis) [88, 89]. A recent large screening study of IBD patients from Canada detected nonalcoholic fatty liver disease in 33% of them, with 12% fibrosis [90]. Therefore, clinicians should be vigilant in screening patients with IBD for these diseases, as well as for cholelithiasis. A disturbed metabolism in IBD patients is causing these diseases to occur in concordance with rapid and large weight changes and steroid use. The prevalence of all liver disease in IBD is probably around 20% [91], among them drug-induced liver disease, vein thrombosis of the hepatic or portal, liver amyloidosis, and granulomatous hepatitis. Autoimmune hepatitis occurs also more frequently in IBD patients, associated with IBD diseases or with PSC.

Primary Sclerosing Cholangitis

PSC is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra- and/or extrahepatic biliary ducts of unknown origin [92].

Its diagnosis is based on a combination of typical symptoms and elevated serum markers of cholestasis (AP, γ GT) not otherwise explained, characteristic bile

duct changes in MRCP (or ERCP), and histological features (if required due to a normal cholangiogram).

More than 70% of PSC patients have IBD (75% UC) in European population, whereas the opposite is only around 1–3% (5% for UC). This explains the European guidelines suggesting an endoscopy at diagnosis of PSC and then every 3–5 years [93]. This diseases' association established since the sixties [94] exhibits a very specific IBD phenotype: a mildly active pancolitis with a right-to-left inflammatory gradient associated with a greater incidence of backwash ileitis and rectal sparing [95]. The evolution of the liver disease is completely asymptomatic and can only be detected when the persistence of abnormal cholestatic pattern of the liver tests is further investigated with MRCP [96] and liver biopsy (for small-duct PSC) [25].

The hallmark of PSC associated with IBD is the higher risk of developing cancers and for 50% of them it will be the cause of death, in order of frequency and risks [97]: cholangiocarcinoma (161 \times) [98], pancreas (14 \times), colorectal carcinoma (11 \times), gallbladder, and hepatocellular carcinoma. These data are based on a cohort study from Sweden [99, 100], which had included 604 PSC patients from 10 hospital between 1970 and 1998, and the colorectal cancer risk assessed by a meta-analysis [101] has also been confirmed by a French study [102] with 75 PSC-IBD patients during a >40-year follow-up (1963–2006). Whereas colorectal cancer and gallbladder cancer [103], colonoscopy, ideally with chromoendoscopy, and ultrasound are recommended annually [25, 93, 104, 105], for cholangiocarcinoma annual surveillance using imaging (MRCP or US in a 12–24 month interval) and CA 19–9 is now being suggested [25, 105, 106] but has not reach the level of international recommendations and must therefore be considered with caution. For other hepatic cancer recent data from the Mayo clinic demonstrated also an impact of screening with imaging modalities [107].

As no efficient treatment exists and the course of disease is unpredictable, liver transplantation remains the final treatment of PSC-induced end-stage disease or hepatocarcinoma. Unfortunately, the disease will eventually recurs on the graft (about 20% at 5 years). The controversy concerning the ursodeoxycholic acid based on a placebo-controlled trial published in 1997 showing no survival benefit [108, 109] is not solved by the international recommendations: the American association recommends against it [110], whereas the European association let it open to the discretion of the physician [25, 111]. In real practice, most experts suggest a dosage of 15 mg/kg [106]. There is a need for a better understanding of the

mechanistical cause, and new more relevant clinical endpoints are [112] for incoming studies on new agents. One part of the solution could potentially come through the modulation of the microbiome and or bile acids, as it is now considered as part of the etiopathogenesis of this disease [113, 114]. In example, oral vancomycin has been tested in a small cohort of children with a substantial benefit; however, a long-term use remains questionable [105]. The finding of aberrant expression of gut-restricted receptors for the adhesion molecule, such as $\alpha 4\beta 7$, within the liver leads to a new hope when using the $\alpha 4\beta 7$ monoclonal antibody, vedolizumab. The most recent data with an only 12-month follow-up showed only a slight impact on PSC-IBD. However, the lack of long-term follow-up endpoints such as end-stage liver disease, transplantation, and mortality could not be assessed [114].

Associated symptoms, such as pruritus, fatigue, and metabolic bone disease linked to PSC, need to be adequately managed by the physician. Cholestyramine (4 g once or twice daily) should be started and, if unsuccessful, rifampicin, sertraline, and naltrexone are good alternatives. Calcium and vitamin D intake should be optimized and associated with enough physical exercise. Bone densitometry should be performed every 2–3 years and in cases of significant finding (osteopenia/porosis) an appropriate bisphosphonate treatment initiated. Advanced stage disease leads to recurrent bacterial cholangitis as well as additional burden of a secondary biliary cirrhosis. Endoscopic treatments have some relevance has recently summarized in European Guidelines with balloon dilation rather than stents which induce more complications [25, 93]. However, the frequency of these interventions should be balanced with the risk of being iatrogenic.

Ophthalmological Manifestations

Up to 2–5% of patients with IBD suffer from ocular manifestations, which include episcleritis and uveitis [55, 84, 115]. CD patients present more often with ocular manifestations (3.5–6.3%) than UC patients (1.6–4.6%) [2, 52, 55, 115–117]. Patients aged over 40 years have more likely iritis/uveitis than those aged <40 years [118].

Episcleritis and Scleritis

Episcleritis is defined as a painless hyperemia of the conjunctiva and sclera. Episcleritis is not associated with changes of the visus. CD patients present more often with episcleritis than UC patients [119]. Since episcleritis often parallels the underlying IBD, it does not need a specific

therapy other than treating the underlying IBD. Scleritis on the other hand affects the deeper layers of the eye. Patients present with severe ocular pain and tenderness to palpation [120]. Scleritis can cause changes of the visus. Early diagnosis is therefore pivotal. If not treated, severe complications such as scleromalacia, retinal detachment, or optic nerve swelling may occur. It is therefore mandatory to start early and aggressive therapy. Disease-specific treatment and topical steroid therapy usually provide prompt relief of symptoms. In case of impairment of vision, the presence of scleritis must be suspected, and prompt referral to an ophthalmologist is mandatory to avoid vision loss.

Uveitis

Uveitis is less common than episcleritis and occurs in 0.5–3% of patients with IBD. Anterior uveitis is the most common ocular manifestations of IBD. Uveitis is divided into 4 different manifestations: (i) anterior uveitis with a main site of inflammation in the anterior chamber, (ii) intermediate uveitis, where the inflammation is primary in the vitreous region, (iii) posterior uveitis, where retina and chorea are primarily involved, and (iv) panuveitis with its primary site of inflammation including anterior chamber, vitreous, retina, and choroid. The activity of uveitis is independent of the underlying IBD activity. Patients usually complain of pain and in case of iritis (anterior uveitis) of photophobia, red eye, blurred vision, and floaters (mooches volantes). A small number of treatment options in IBD patients suffering from uveitis have been published [121–128]. Prompt diagnosis and treatment with topical and systemic corticosteroids is necessary to prevent progression to blindness. Steroid refractory cases are treated with cyclosporine A. Successful use of infliximab for IBD-associated uveitis was demonstrated in a CD patient with uveitis and sacroiliitis [128].

Other Rare EIM

Other rare EIM of IBD have been described in the other organs. Their management is more disease specific and will not be detailed here. Neurological EIM are mostly peripheral neuropathy [129], whereas central demyelinating diseases have been shown as well [130]. Pulmonary involvement exists with reports involving different parts of the bronchial tree from the glottis to small airways. In particular, interstitial pneumonitis has been suggested 20–55% of IBD patients [131], the most frequent remaining drug induced (5-ASA compounds, methotrexate, or anti-TNF alpha agents) [132] and infections. IBD patients are at increased risk of cardiovascular events (mainly ve-

nous and arterial thromboembolism, myocardial infarction) which are more linked to the chronic inflammatory pattern of the disease and less to very rare associated cardiovascular diseases [25, 133]. Finally, pancreatitis associated with IBD could also be considered as EIM after inclusion of biliary pancreatitis, drug-induced (i.e., azathioprine, amino salicylates) or autoimmune cause [134, 135].

Discussion and Conclusion

In the present review, we illustrate an update on the management of EIM of IBD patients. Whereas no new effective treatments has been identified so far for treatment of PSC but a high importance of performing cancer surveillance, on the other hand, a bench of new molecules will emerge with an overlapping effect on gastrointestinal and rheumatological diseases. This later constellation is also linked to uveitis, which suggested that this EIM will probably also be improved by these therapies. The future

is of the management of EIM remains bright and the understanding of their management is central to the gastroenterologist as it occurs in almost half of IBD patients and sometimes drives unilaterally treatment indication.

Acknowledgment

None.

Disclosure Statement

Authors declare no conflict of interest.

Author Contributions

P.J., J.Z., and S.R.V. reviewed the literature and prepared the draft of the manuscript. All co-authors reviewed the paper and improved its scientific and clinical content.

References

- Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. *Am J Gastroenterol*. 2001 Apr;96(4):1116–22.
- Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol*. 2011 Jan;106(1):110–9.
- Vavricka SR, Rogler G, Gantenbein C, Sporerri M, Prinz Vavricka M, Navarini AA, et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. *Inflamm Bowel Dis*. 2015 Aug;21(8):1794–800.
- Ditisheim S, Fournier N, Juillerat P, Pittet V, Michetti P, Gabay C, et al.; Swiss IBD Cohort Study Group. Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study. *Inflamm Bowel Dis*. 2015 Nov;21(11):2598–604.
- Ford DK, Vallis DG. The clinical course of arthritis associated with ulcerative colitis and regional ileitis. *Arthritis Rheum*. 1959 Dec;2(6):526–36.
- Wright V, Moll J. *Seronegative Polyarthritis*. Amsterdam: North Holland Publishing Company; 1976.
- De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. *Gastroenterology*. 1996 Jun;110(6):1696–703.
- Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. *Ann Rheum Dis*. 2015 Jan;74(1):65–73.
- Laukens D, Georges M, Libioule C, Sandor C, Mni M, Vander Cruyssen B, et al. Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis. *PLoS One*. 2010 Nov;5(11):e13795.
- Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. *Ann Rheum Dis*. 2005 Jun;64(6):930–5.
- Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science*. 2006 Dec;314(5804):1461–3.
- Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. *Expert Rev Gastroenterol Hepatol*. 2019 Apr;13(4):307–17.
- Baeten D, Demetter P, Cuvelier CA, Kruihof E, Van Damme N, De Vos M, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. *J Pathol*. 2002 Mar;196(3):343–50.
- Fabrick BO, van Bruggen R, Deng DM, Lichtenberg AJ, Nazmi K, Schornagel K, et al. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. *Blood*. 2009 Jan;113(4):887–92.
- Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. *Nat Rev Immunol*. 2006 Mar;6(3):244–51.
- Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, et al. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2018 Apr;24(9):1876–82.
- Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. *J Immunol*. 2001 Apr;166(7):4650–7.
- Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. *Gut*. 1998 Mar;42(3):387–91.
- van Erp SJ, Brakenhoff LK, van Gaalen FA, van den Berg R, Fidler HH, Verspaget HW, et al. Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Follow-up Study. *J Crohns Colitis*. 2016 Feb;10(2):166–75.
- Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? *Eur J Clin Pharmacol*. 2009 Oct;65(10):963–70.

- 21 Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? *Am J Gastroenterol*. 2009 May;104(5):1298–313.
- 22 Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. *Gut*. 1997 May;40(5):619–22.
- 23 Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. *Am J Gastroenterol*. 2000 Aug;95(8):1949–54.
- 24 Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation. *Aliment Pharmacol Ther*. 2018 Jun;47(11):1428–39.
- 25 Harbord M, Anness V, Vavricka SR, Allez M, Barreiro-de Acosta M, Baberg KM, et al.; European Crohn's and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. *J Crohn's Colitis*. 2016 Mar;10(3):239–54.
- 26 Sandborn WJ, Stenson WF, Brynkvov J, Lorenz RG, Steidle GM, Robbins JL, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. *Clin Gastroenterol Hepatol*. 2006 Feb;4(2):203–11.
- 27 El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. *Am J Gastroenterol*. 2006 Feb;101(2):311–7.
- 28 van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017 Jun;76(6):978–91.
- 29 McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. *Cochrane Database Syst Rev*. 2014 Aug;(8):CD003459.
- 30 Van den Bosch F, Kruihof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. *Lancet*. 2000 Nov;356(9244):1821–2.
- 31 Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. *Ann Rheum Dis*. 2004 Dec;63(12):1664–9.
- 32 Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbachner T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. *Am J Gastroenterol*. 2002 Oct;97(10):2688–90.
- 33 Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, et al.; Swiss IBD Cohort Study Group. Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. *Eur J Gastroenterol Hepatol*. 2010 Nov;22(11):1352–7.
- 34 Löfberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. *Inflamm Bowel Dis*. 2012 Jan;18(1):1–9.
- 35 Louis EJ, Reinisch W, Schwartz DA, Löfberg R, Robinson AM, Berg S, et al. Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies. *Adv Ther*. 2018 Apr;35(4):563–76.
- 36 Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al.; Swiss IBD Cohort Study Group. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis*. 2017 Jul;23(7):1174–81.
- 37 Thiebault H, Boyard-Lasselín P, Guignant C, Guillaume N, Wacrenier A, Sabbagh C, et al. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab. *Eur J Gastroenterol Hepatol*. 2016 Aug;28(8):876–81.
- 38 Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum*. 2008 Nov;58(11):3402–12.
- 39 Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. *Ann Rheum Dis*. 2014 Jun;73(6):1107–13.
- 40 Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis*. 2014 Jan;73(1):39–47.
- 41 Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. *Aliment Pharmacol Ther*. 2010 Aug;32(3):384–93.
- 42 Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. *Clin Gastroenterol Hepatol*. 2010 Aug;8(8):688–95.e2.
- 43 Tadbiri S, Peyrin-Biroulet L, Serrero M, Filipi J, Pariente B, Roblin X, et al.; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. *Aliment Pharmacol Ther*. 2018 Feb;47(4):485–93.
- 44 Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. *Gut*. 2017 Dec;66(12):2179–87.
- 45 van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendriks T, et al. Tocilizumab in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. *Ann Rheum Dis*. 2017 Aug;76(8):1340–7.
- 46 Peyrin-Biroulet L, Danese S, Louis E, Higgins PDR, Dubinsky M, Cataldi F, et al. Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn's disease: data from the CELEST study. *J Crohn's Colitis*. 2019;13:S57.
- 47 Hueber W, Sands BE, Lewitzky S, Vandemeulebroeck M, Reinisch W, Higgins PD, et al.; Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut*. 2012 Dec;61(12):1693–700.
- 48 Kumar P, Monin L, Castillo P, Elseiginy W, Horne W, Eddens T, et al. Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation. *Immunity*. 2016 Mar;44(3):659–71.
- 49 Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. *Immunity*. 2015 Oct;43(4):739–50.
- 50 Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. *Ann Rheum Dis*. 2018 Sep;77(9):1295–302.
- 51 Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019 Feb;71(2):258–70.
- 52 Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. *Medicine (Baltimore)*. 1976 Sep;55(5):401–12.
- 53 Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. *Gastroenterology*. 2002 Sep;123(3):714–8.

- 54 Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. *Medicine (Baltimore)*. 2008 Sep; 87(5):281–93.
- 55 Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. *J Clin Gastroenterol*. 1996 Jul;23(1): 29–34.
- 56 Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. *Clin Dermatol*. 2008 May-Jun;26(3):265–73.
- 57 Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. *J Pediatr Gastroenterol Nutr*. 2003 Aug;37(2):150–4.
- 58 Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. *J Eur Acad Dermatol Venerol*. 2007 Mar;21(3):408–10.
- 59 Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab. *Nat Clin Pract Gastroenterol Hepatol*. 2008 May;5(5):278–81.
- 60 Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. *Clin Exp Dermatol*. 2006 Nov;31(6): 823–4.
- 61 Jorizzo JL, Solomon AR, Zanolli MD, Leshin B. Neutrophilic vascular reactions. *J Am Acad Dermatol*. 1988 Dec;19(6):983–1005.
- 62 Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. *Medicine (Baltimore)*. 2000 Jan;79(1): 37–46.
- 63 Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. *Can J Gastroenterol*. 2005 Oct;19(10): 603–6.
- 64 Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. *Am J Gastroenterol*. 2006 May;101(5):1012–23.
- 65 Callen JP. Pyoderma gangrenosum. *Lancet*. 1998 Feb;351(9102):581–5.
- 66 Orchard T. Extraintestinal complications of inflammatory bowel disease. *Curr Gastroenterol Rep*. 2003 Dec;5(6):512–7.
- 67 Powell RJ, Holbrook MR, Stevens A. Pyoderma gangrenosum and its treatment. *Lancet*. 1997 Dec;350(9093):1720–1.
- 68 Friedman S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. *Inflamm Bowel Dis*. 2001 Feb;7(1):1–7.
- 69 Wollina U, Haroske G. Pyoderma gangrenosum. *Curr Opin Rheumatol*. 2011 Jan;23(1): 50–6.
- 70 Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. *Am J Gastroenterol*. 2003 Aug;98(8):1821–6.
- 71 Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. *Aliment Pharmacol Ther*. 2001 Oct;15(10):1639–46.
- 72 Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. *Gut*. 2006 Apr;55(4):505–9.
- 73 Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellström PM. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. *Scand J Gastroenterol*. 2002 Sep;37(9):1108–10.
- 74 Martin D, Handler T, McDermott J. Leucocytoclastic vasculitis in severe ulcerative colitis. *Mil Med*. 2011 May;176(5):581–3.
- 75 Juillerat P, Christen-Zäch S, Troillet FX, Gallo-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. *Dermatology*. 2007;215(3):245–51.
- 76 Lopez San Roman A, Bermejo F, Aldanondo I, Carrera E, Boixeda D, Munoz Zato E. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. *Rev Esp Enferm Dig*. 2004 Jun;96(6):420–2.
- 77 Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. *Inflamm Bowel Dis*. 2009 Jun;15(6): 803–6.
- 78 Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: two birds with one stone. *World J Gastroenterol*. 2009 May;15(18):2293–5.
- 79 Vavricka SR, Scharl M, Gubler M, Rogler G. Biomarkers for extraintestinal manifestations of IBD. *Curr Drug Targets*. 2014;15(11):1064–73.
- 80 Benton EC, Rutherford D, Hunter JA. Sweet's syndrome and pyoderma gangrenosum associated with ulcerative colitis. *Acta Derm Venereol*. 1985;65(1):77–80.
- 81 Becuwe C, Delaporte E, Colombel JF, Piette F, Cortot A, Bergoend H. Sweet's syndrome associated with Crohn's disease. *Acta Derm Venereol*. 1989;69(5):444–5.
- 82 Banet DE, McClave SA, Callen JP. Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease. *J Rheumatol*. 1994 Sep; 21(9):1766–8.
- 83 Kemmett D, Hunter JA. Sweet's syndrome: a clinicopathologic review of twenty-nine cases. *J Am Acad Dermatol*. 1990 Sep;23(3 Pt 1): 503–7.
- 84 Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. *Gastroenterol Clin North Am*. 2002 Mar;31(1):307–27.
- 85 VanHale HM, Rogers RS 3rd, Zone JJ, Greipp PR. Pyostomatitis vegetans. A reactive mucosal marker for inflammatory disease of the gut. *Arch Dermatol*. 1985 Jan;121(1):94–8.
- 86 Vavricka SR, Manser CN, Hediger S, Vögelin M, Scharl M, Biedermann L, et al. Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. *Inflamm Bowel Dis*. 2013 Dec;19(13):2768–77.
- 87 Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. *J Am Acad Dermatol*. 2013 Feb;68(2):211.e1–33.
- 88 Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2014 Jul;40(1):3–15.
- 89 Restellini S, Chazouilleres O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. *Liver Int*. 2017 Apr;37(4):475–89.
- 90 Saroli Palumbo C, Restellini S, Chao CY, Aruljothy A, Lemieux C, Wild G, et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. *Inflamm Bowel Dis*. 2019 Jan;25(1):124–33.
- 91 Silva J, Brito BS, Silva IN, Nóbrega VG, da Silva MC, Gomes HD, et al. Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients. *BioMed Res Int*. 2019 Jan;2019: 7604939.
- 92 Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. *Lancet*. 2013 Nov;382(9904):1587–99.
- 93 Aabakken L, Karlsen TH, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau JM, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. *Endoscopy*. 2017 Jun;49(6):588–608.
- 94 Smith MP, Loe RH. Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. *Am J Surg*. 1965 Aug;110(2):239–46.
- 95 Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. *Gut*. 2005 Jan;54(1):91–6.
- 96 Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. *Radiology*. 2010 Aug;256(2):387–96.
- 97 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. *World J Gastroenterol*. 2019 Feb;25(6): 659–71.

- 98 Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. *Am J Gastroenterol*. 2016 May;111(5):705–11.
- 99 Bergquist A, Ekblom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. *J Hepatol*. 2002 Mar;36(3):321–7.
- 100 de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. *Liver Int*. 2012 Mar;32(3):441–8.
- 101 Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. *Gastrointest Endosc*. 2002 Jul;56(1):48–54.
- 102 Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, Poupon R, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. *World J Gastroenterol*. 2008 Jun;14(22):3497–503.
- 103 Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. *Am J Gastroenterol*. 2012 Mar;107(3):431–9.
- 104 Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. *Aliment Pharmacol Ther*. 2011 Sep;34(5):497–508.
- 105 Strassburg CP, Beckebaum S, Geier A, Gotthardt D. S2k Leitlinie Autoimmune Lebererkrankungen. *Z Gastroenterol*. 2017 Nov;55(11):1135–226.
- 106 Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. *Am J Gastroenterol*. 2015 May;110(5):646–59.
- 107 Ali AH, Tabibian JH, Nasser-Ghods N, Lennon RJ, DeLeon T, Borad MJ, et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. *Hepatology*. 2018 Jun;67(6):2338–51.
- 108 Lindor KD; Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. *N Engl J Med*. 1997 Mar;336(10):691–5.
- 109 Poropat G, Giljaca V, Stimac D, Glud C. Bile acids for primary sclerosing cholangitis. *Cochrane Database Syst Rev*. 2011 Jan;(1):CD003626.
- 110 Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. *Hepatology*. 2010 Feb;51(2):660–78.
- 111 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. *J Hepatol*. 2009 Aug;51(2):237–67.
- 112 Ponsioen CY, Lindor KD, Mehta R, Dimick-Santos L. Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. *Hepatology*. 2018 Sep;68(3):1174–88.
- 113 Hov JR, Karlsen TH. The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts. *Semin Liver Dis*. 2017 Nov;37(4):314–31.
- 114 Torres J, Palmela C, Brito H, Bao X, Ruiqi H, Moura-Santos P, et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. *United European Gastroenterol J*. 2018 Feb;6(1):112–22.
- 115 Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. *Ann Ophthalmol*. 1982 Apr;14(4):356–60.
- 116 Monsén U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. *Am J Gastroenterol*. 1990 Jun;85(6):711–6.
- 117 Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. *Gastroenterology*. 1979 Oct;77(4 Pt 2):914–20.
- 118 Bernstein CN. Extraintestinal manifestations of inflammatory bowel disease. *Curr Gastroenterol Rep*. 2001 Dec;3(6):477–83.
- 119 Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. *World J Gastroenterol*. 2006 Aug;12(30):4819–31.
- 120 Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. *Inflamm Bowel Dis*. 2004 Mar;10(2):135–9.
- 121 Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. *Arthritis Rheum*. 2005 Aug;52(8):2447–51.
- 122 Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. *Br J Ophthalmol*. 2007 Mar;91(3):319–24.
- 123 Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. *Ophthalmology*. 2006 May;113(5):860–4.e2.
- 124 Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis. *Rheumatology (Oxford)*. 2006 Aug;45(8):982–9.
- 125 Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. *Ophthalmology*. 2006 Feb;113(2):308–14.
- 126 Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. *Cytokine*. 2006 Feb;33(4):231–7.
- 127 Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. *J Rheumatol*. 2007 May;34(5):1146–50.
- 128 Fries W, Giofré MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. *Am J Gastroenterol*. 2002 Feb;97(2):499–500.
- 129 Gondim FA, Brannagan TH 3rd, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. *Brain*. 2005 Apr;128(Pt 4):867–79.
- 130 Geissler A, Andus T, Roth M, Kullmann F, Caesar I, Held P, et al. Focal white-matter lesions in brain of patients with inflammatory bowel disease. *Lancet*. 1995 Apr;345(8954):897–8.
- 131 Desai D, Patil S, Udwadia Z, Maheshwari S, Abraham P, Joshi A. Pulmonary manifestations in inflammatory bowel disease: a prospective study. *Indian J Gastroenterol*. 2011 Sep;30(5):225–8.
- 132 Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. *J Clin Med*. 2018 Oct;7(10):E356.
- 133 Bunu DM, Timofte CE, Ciociu M, Floria M, Tarniceriu CC, Barboi OB, et al. Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies. *Gastroenterol Res Pract*. 2019 Jan;2019:3012509.
- 134 Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. *J Clin Gastroenterol*. 1993 Dec;17(4):286–91.
- 135 Munk EM, Pedersen L, Floyd A, Nørgård B, Rasmussen HH, Sørensen HT. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. *Am J Gastroenterol*. 2004 May;99(5):884–8.
- 136 Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. *Clin Gastroenterol Hepatol*. 2014 Sep;12(9):1485–93.e2.
- 137 Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. *Gut*. 2017 Jun;66(6):1049–59.

- 138 Panés J, D'Haens GR, Higgins PD, Mele L, Moscariello M, Chan G, et al. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. *Aliment Pharmacol Ther.* 2019 Feb; 49(3):265–76.
- 139 Sands BE, Panes J, Higgins PD, Moscariello M, Chan G, Su CY, et al. Post-Hoc Analysis of Tofacitinib Crohn's Disease Phase 2 Induction Efficacy in Subgroups with Baseline Endoscopic or Biomarker Evidence of Inflammation. *Gastroenterology.* 2018;154(1):S81.
- 140 Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al.; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med.* 2017 May; 376(18):1723–36.
- 141 Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, et al. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. *J Crohn's Colitis.* 2018 Jan;12(2):145–56.
- 142 van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al.; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med.* 2012 Aug; 367(6):508–19.
- 143 Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. *J Am Acad Dermatol.* 2016 May;74(5):841–50.
- 144 Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al.; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. *Br J Dermatol.* 2015 Oct;173(4):949–61.
- 145 Sandborn WJ, Feagan BG, Panes J, D'Haens GR, Colombel JF, Zhou Q, et al. 874h - Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: results from Celest. *Gastroenterology.* 2017;152(5 Suppl 1):S1308–9.
- 146 Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, et al. Op195 efficacy And Safety Of Upadacitinib As An Induction Therapy For Patients With Moderately-To-Severely Active Ulcerative Colitis: Data From The Phase 2b Study U-Achieve. *United European Gastroenterol J.* 2018;6(8_Suppl):A1–134.
- 147 Sandborn WJ, Schreiber S, Lee SD, Lindsay JO, Hebuterne X, Zhou W, et al. Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study. *J Crohn's Colitis.* 2019;13 Suppl 1:S9.
- 148 Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet.* 2018 Jun; 391(10139):2503–12.
- 149 Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. *J Immunol.* 2013 Oct;191(7):3568–77.
- 150 Vermeire S, Schreiber S, Petryka R, Kuehbachner T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. *Lancet.* 2017 Jan;389(10066):266–75.
- 151 Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *N Engl J Med.* 2017 Feb;376(7):652–62.
- 152 Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislaw M, et al. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. *Arthritis Rheumatol.* 2017 Mar;69(3):506–17.
- 153 Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. *Br J Dermatol.* 2016 Jun;174(6):1266–76.
- 154 Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, et al.; Peficitinib-UC Study Group. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. *J Crohn's Colitis.* 2018 Nov;12(10):1158–69.
- 155 Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, et al. Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards. *Arthritis Rheumatol.* 2018;70:2.
- 156 Danese S, Neurath M, Kopon A, Zakko S, Simmons T, Fogel R, et al. Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study. *J Crohn's Colitis.* 2018;12 Suppl 1:S4–5.
- 157 Danese S, Neurath M, Kopon A, Zakko SF, Simmons TC, Fogel RP, et al. Apremilast For Active Ulcerative Colitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. *Gastroenterology.* 2018; 154(6):S167.
- 158 Genovese MC, Jarosova K, Cieslak D, Alper J, Kivitz A, Hough DR, et al. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. *Arthritis Rheumatol.* 2015 Jul; 67(7):1703–10.
- 159 Pathan E, Abraham S, Van Rossen E, Withington R, Keat A, Charles PJ, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. *Ann Rheum Dis.* 2013 Sep;72(9):1475–80.
- 160 Mease PJ, Marzo-Ortega H, Poder A, Van den Bosch F, Wollenhaupt J, Lespessailles E, et al. Apremilast, An Oral Phosphodiesterase-4 Inhibitor, Is Associated With Long-Term (156-Week) Improvements In Bath Ankylosing Spondylitis Disease Activity Index Score In Subjects With Psoriatic Arthritis: Pooled Results From Three Phase III Randomised Controlled Trials. *Rheumatology.* 2018;57 Suppl 3:2.
- 161 Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum.* 2012 Oct;64(10):3156–67.
- 162 Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. *Ann Rheum Dis.* 2014 Jun; 73(6):1020–6.
- 163 Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. *J Rheumatol.* 2015 Mar;42(3):479–88.
- 164 Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. *Gastroenterology.* 2004 Apr;126(4):989–96.
- 165 Atreya R, Billmeier U, Rath T, Mudter J, Vieth M, Neumann H, et al. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy. *World J Gastroenterol.* 2015 Dec;21(45):12963–9.
- 166 Szeto MC, Yalçın MD, Khan A, Piotrowicz A. Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis. *Case Reports Immunol.* 2016;2016:7562123.

- 167 Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis*. 2010 Jan;69(1):88–96.
- 168 Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. *Ann Rheum Dis*. 2017 Mar;76(3):504–10.
- 169 Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Tocilizumab (Tcz) Is Not Effective For The Treatment Of Ankylosing Spondylitis (As): Results Of A Phase 2, International, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. *Ann Rheum Dis*. 2013;71 Suppl 3:110–1.
- 170 Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al.; UNIFI-IM-UNIFI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *N Engl J Med*. 2016 Nov;375(20):1946–60.
- 171 Smolen JS, Agarwal SK, Ilivanova E, Xu XL, Miao Y, Zhuang Y, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. *Ann Rheum Dis*. 2017 May;76(5):831–9.
- 172 McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al.; PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013 Aug;382(9894):780–9.
- 173 Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al.; PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Ann Rheum Dis*. 2014 Jun;73(6):990–9.
- 174 Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*. 2008 May;371(9625):1665–74.
- 175 Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*. 2008 May;371(9625):1675–84.
- 176 Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. *Inflamm Bowel Dis*. 2015 Jun;21(6):1329–40.
- 177 Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. *J Invest Dermatol*. 2012 Feb;132(2):304–14.
- 178 Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. *Lancet*. 2017 Apr;389(10080):1699–709.
- 179 Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. *Lancet*. 2018 Aug;392(10148):650–61.
- 180 Mease PJ, Kellner H, Morita A, Kivitz AJ, Papp KA, Aslanyan S, et al. OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. *Ann Rheum Dis*. 2018;77:200–1.
- 181 Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, et al. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. *Gastroenterology*. 2017 Jul;153(1):77–86. e6.
- 182 Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. *J Am Acad Dermatol*. 2017 Mar;76(3):405–17.
- 183 Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. *J Am Acad Dermatol*. 2017 Mar;76(3):418–31.
- 184 Deodhar A, Gottlieb AB, Boehrlicke WH, Dong B, Wang Y, Zhuang Y, et al. Efficacy And Safety Results Of Guselkumab In Patients With Active Psoriatic Arthritis Over 56 Weeks From A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study. *Ann Rheum Dis*. 2018;77:201.
- 185 Sands BE, Sandborn WJ, Peyrin-Biroulet L, Higgins PD, Hirai F, Belin R, et al. OP1003 Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease. *Gastroenterology*. 2019;156(6):S216.
- 186 D'Haens G, Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, et al. Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. *J Crohn's Colitis*. 2019;13 Suppl 1:S26–7.
- 187 Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens G, et al. Extended Treatment With Mirikizumab In Patients With Moderately-To-Severely Active Ulcerative Colitis: Results From A Phase 2 Trial. *Gastroenterology*. 2019;156(6):S1094.
- 188 Rich P, Maari C, Leonardi CL, Klekotka P, Patel D, Li J, et al. Efficacy, safety, and quality of life in patients with moderate-to-severe plaque psoriasis treated with mirikizumab (LY3074828) in a phase 2 study. *J Am Acad Dermatol*. 2018;79(3 suppl. 1):AB126.
- 189 Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. *Am J Gastroenterol*. 2016 Nov;111(11):1599–607.
- 190 Wei JC, Kim TH, Kishimoto M, Morishige T, Ogusu N, Kobayashi S. OP0234 Efficacy And Safety Of Brodalumab, An Anti-Interleukin-17 Receptor A Monoclonal Antibody, In Patients With Axial Spondyloarthritis: A 16 Week Results Of A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. *Ann Rheum Dis*. 2019;78:195.
- 191 Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. *N Engl J Med*. 2014 Jun;370(24):2295–306.
- 192 Blanco FJ, Mörlicke R, Dokoupilova E, Codding C, Neal J, Andersson M, et al. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. *Arthritis Rheumatol*. 2017 Jun;69(6):1144–53.
- 193 Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al.; MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med*. 2015 Dec;373(26):2534–48.

- 194 McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al.; FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015 Sep;386(9999):1137–46.
- 195 Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. *Gastroenterology*. 2000 Feb; 118(2):274–8.
- 196 Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*. 2009 Jun;68(6):777–83.